Drug intelligence / Profile preview

NM402

Development stage: Preclinical
Lead developer: Neuramedy
Modality: Small Molecules

Overview

NM402 (also known as NM-402) is a preclinical-stage alpha-synuclein modulator being developed by Neuramedy Co., Ltd. for the treatment of nervous system disorders, specifically synucleinopathies such as Parkinson's disease. The drug is designed to target and modulate the alpha-synuclein protein, which is known to form toxic aggregates in the brains of patients with these neurodegenerative conditions. As of the current research stage, NM402 is in the discovery phase, focusing on its potential to alter disease progression by addressing the underlying protein pathology.

Targets

SNCA (Alpha-synuclein)

Beyond the preview

Go deeper on NM402.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NM402.

Explore the full profile